Supernus Pharm (SUPN) Stock Price, Quote & News

Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the mon...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 838 2500

Website: www.supernus.com

Address:

9715 Key West Avenue, Rockville, United States

txbondman Jun. 29 at 2:35 PM

bot $AVGO, $CIEN, $EVR, $FN and $SUPN to double down; (Don't try this at home!!)

0 · Reply

Noli75145 Jun. 1 at 1:01 PM

$SUPN Adamantane carboxamides are an investigational class of small-molecule antiviral drugs that block Ebola virus (EBOV) cell entry. They function by binding directly to the viral glycoprotein (GP) or by targeting the host's Niemann-Pick C1 (NPC1) protein, which the virus requires to fuse with endosomal membranes.Key CharacteristicsMechanism of Action: They inhibit viral entry by preventing the interaction between the proteolytically cleaved Ebola glycoprotein and the host's receptor, halting the infection.

0 · Reply

NorthStarStats May. 8 at 12:35 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. The scanner is showing mixed results over the last few days and that aligns with what we are seeing in the market. $NAMS Score 100, $PTC Score 100, $IT Score 98, $SUPN Score 95, $RCL Score 95

0 · Reply

SuperGreenToday May. 8 at 1:35 AM

$SUPN Share Price: $52.28 Contract Selected: Dec 18, 2026 $55 Calls Buy Zone: $4.17 – $5.15 Target Zone: $6.89 – $8.42 Potential Upside: 56% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Merlintrader May. 6 at 10:48 AM

$ADPT $SUPN, $RLAY : Three Q1 2026 Earnings Reports, Three Different Biotech Risk Profiles https://www.merlintrader.com/supn-rlay-adpt-three-q12026-earnings/

0 · Reply

Biocontrol May. 5 at 10:49 PM

$SUPN crushed it. Been holding this one since Qelbree was P3. Only wish I had more.

0 · Reply

StocktwitsEarnings May. 5 at 8:15 PM

$SUPN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.04 up 80.95% YoY • Reported revenue of $207.71M up 38.63% YoY • Supernus Pharmaceuticals reiterates its full year 2026 financial guidance, projecting total revenues between $840M and $870M, with adjusted operating earnings (non-GAAP) expected to be $140M to $170M.

0 · Reply

MrMaglue May. 5 at 8:09 PM

$SUPN https://ir.supernus.com/news-releases/news-release-details/supernus-announces-first-quarter-2026-financial-results

0 · Reply

BillionerOfKing May. 5 at 4:52 PM

$SUPN Current Stock Price: $49.22 Contracts to trade: $50.0 SUPN May 15 2026 Call Entry: $0.90 Exit: $1.32 ROI: 47% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Doozio Mar. 5 at 2:49 PM

$SUPN thing about final Thursday 🐑 🎁s. 🐒🍌🧠⏰♾️

0 · Reply

Supernus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:30 PM EDT - 5 weeks ago

Supernus Pharmaceuticals to Participate in June Investor Conferences

May 12, 2026, 6:40 PM EDT - 7 weeks ago

Supernus Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 6, 2026, 5:00 PM EDT - 2 months ago

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

May 5, 2026, 4:30 PM EDT - 2 months ago

Supernus Pharmaceuticals Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Supernus Pharmaceuticals Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Supernus Pharmaceuticals Quarterly report: Q1 2026

May 5, 2026, 4:05 PM EDT - 2 months ago

Supernus Announces First Quarter 2026 Financial Results

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Supernus Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Supernus Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 4:15 PM EDT - 2 months ago

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

2026-04-07T21:30:18.000Z - 3 months ago

Supernus enters into asset purchase agreement with Navitor

Mar 11, 2026, 2:00 PM EDT - 4 months ago

Supernus Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 2:30 PM EST - 4 months ago

Supernus Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-25T12:47:22.000Z - 4 months ago

Supernus price target raised to $65 from $60 at TD Cowen

Feb 24, 2026, 4:30 PM EST - 4 months ago

Supernus Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

Supernus Pharmaceuticals Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

Supernus Pharmaceuticals Earnings release: Q4 2025

Feb 24, 2026, 4:05 PM EST - 4 months ago

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 6:15 PM EST - 4 months ago

Supernus Pharmaceuticals to Participate in March Investor Conferences

Feb 12, 2026, 4:35 PM EST - 5 months ago

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026

Feb 9, 2026, 11:14 AM EST - 5 months ago

Lunai Bioworks, Inc. Issues Letter to Shareholders

Jan 15, 2026, 10:31 AM EST - 6 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

2025-12-19T12:56:11.000Z - 7 months ago

Supernus price target raised to $55 from $50 at Stifel

Dec 8, 2025, 3:20 PM EST - 7 months ago

Supernus Pharmaceuticals Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025

Dec 3, 2025, 4:05 PM EST - 7 months ago

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

Dec 2, 2025, 4:00 PM EST - 7 months ago

Supernus Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 4:06 PM EST - 8 months ago

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 9:30 AM EST - 8 months ago

Supernus Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 8 months ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Nov 4, 2025, 4:30 PM EST - 8 months ago

Supernus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Supernus Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Supernus Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 8 months ago

Supernus Announces Third Quarter 2025 Financial Results

2025-10-29T10:20:32.000Z - 8 months ago

Supernus initiated with a Buy at BofA

2025-10-23T12:36:16.000Z - 9 months ago

Supernus price target raised to $60 from $45 at TD Cowen

Oct 21, 2025, 5:00 PM EDT - 9 months ago

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

2025-10-09T09:20:17.000Z - 9 months ago

Piper upgrades Supernus on ‘promising’ Onapgo trajectory

2025-10-08T23:35:10.000Z - 9 months ago

Supernus upgraded to Overweight from Neutral at Piper Sandler

2025-09-30T12:45:53.000Z - 9 months ago

Supernus price target raised to $63 from $46 at Cantor Fitzgerald

Sep 4, 2025, 8:45 AM EDT - 10 months ago

Supernus Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Supernus Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

2025-08-29T10:41:02.000Z - 11 months ago

Supernus price target raised to $40 from $36 at Piper Sandler

Aug 27, 2025, 4:15 PM EDT - 11 months ago

Supernus Pharmaceuticals to Participate in September Investor Conferences

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Supernus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Supernus Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Supernus Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 4:05 PM EDT - 11 months ago

Supernus Announces Second Quarter 2025 Financial Results

Jul 31, 2025, 8:44 AM EDT - 1 year ago

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Jul 28, 2025, 8:25 AM EDT - 1 year ago

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Jul 22, 2025, 4:30 PM EDT - 1 year ago

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

Jul 14, 2025, 4:25 PM EDT - 1 year ago

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

Jun 16, 2025, 5:31 PM EDT - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

Jun 16, 2025, 8:30 AM EDT - 1 year ago

Supernus Pharmaceuticals Transcript: M&A Announcement

Jun 16, 2025, 8:30 AM EDT - 1 year ago

Supernus Pharmaceuticals Press release: M&A Announcement

Jun 16, 2025, 8:30 AM EDT - 1 year ago

Supernus Pharmaceuticals Slides: M&A Announcement

Jun 16, 2025, 7:14 AM EDT - 1 year ago

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Jun 4, 2025, 2:00 PM EDT - 1 year ago

Supernus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:30 AM EDT - 1 year ago

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

May 28, 2025, 4:05 PM EDT - 1 year ago

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28, 2025, 4:05 PM EDT - 1 year ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 4:30 PM EDT - 1 year ago

Supernus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Supernus Pharmaceuticals Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Supernus Pharmaceuticals Earnings release: Q1 2025

May 6, 2025, 4:08 PM EDT - 1 year ago

Supernus Announces First Quarter 2025 Financial Results

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Supernus Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Supernus Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 5:14 PM EDT - 1 year ago

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

txbondman Jun. 29 at 2:35 PM

bot $AVGO, $CIEN, $EVR, $FN and $SUPN to double down; (Don't try this at home!!)

0 · Reply

Noli75145 Jun. 1 at 1:01 PM

0 · Reply

NorthStarStats May. 8 at 12:35 PM

0 · Reply

SuperGreenToday May. 8 at 1:35 AM

0 · Reply

Merlintrader May. 6 at 10:48 AM

$ADPT $SUPN, $RLAY : Three Q1 2026 Earnings Reports, Three Different Biotech Risk Profiles https://www.merlintrader.com/supn-rlay-adpt-three-q12026-earnings/

0 · Reply

Biocontrol May. 5 at 10:49 PM

$SUPN crushed it. Been holding this one since Qelbree was P3. Only wish I had more.

0 · Reply

StocktwitsEarnings May. 5 at 8:15 PM

0 · Reply

MrMaglue May. 5 at 8:09 PM

$SUPN https://ir.supernus.com/news-releases/news-release-details/supernus-announces-first-quarter-2026-financial-results

0 · Reply

BillionerOfKing May. 5 at 4:52 PM

0 · Reply

Doozio Mar. 5 at 2:49 PM

$SUPN thing about final Thursday 🐑 🎁s. 🐒🍌🧠⏰♾️

0 · Reply

Doozio Mar. 5 at 2:41 AM

$SUPN thing about chop chop huckleberries n it gets $LGND ary thru da $$$ patterns 🐒🍌🧠⏰♾️

0 · Reply

d_risk Mar. 3 at 5:28 PM

$SUPN - Supernus Pharmaceuticals Inc - 10K - Updated Risk Factors SUPN’s risk profile tightens around ZURZUVAE commercialization and post‑marketing obligations, ONAPGO supply constraints and rising competition (e.g., AbbVie’s Vyalev), heavier reliance on third‑party partners/suppliers, expanding acquisition and goodwill risk, escalating healthcare pricing/regulatory uncertainty (including new Executive Orders and Chevron reversal), and growing patent, litigation, product liability, and cybersecurity exposures. #PharmaceuticalIndustry #ProductCommercialization #SupplyChainRisk #HealthcareRegulation #PatentLitigation 🟢 Added 🟠 Removed https://d-risk.ai/SUPN/10-K/2026-03-02

0 · Reply

txbondman Feb. 25 at 3:09 PM

sld some winners (partial) to take profits. sld $CIEN for a 640% gain; sld $SUPN for a 150% gain;

1 · Reply

Estimize Feb. 25 at 3:01 PM

Wall St is expecting 0.45 EPS for $SUPN Q1 [Reporting 05/12 AMC] http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_co

0 · Reply

Estimize Feb. 25 at 11:03 AM

$SUPN reported 0.85 EPS and 211.57 revenue for Q4. http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_content=SUPN&utm

0 · Reply

StocktwitsEarnings Feb. 24 at 9:22 PM

$SUPN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.07 down -125.00% YoY • Reported revenue of $211.57M up 21.48% YoY • Supernus Pharmaceuticals provided full year 2026 guidance for total revenues of $840M to $870M, operating earnings of $0 to $30M, and adjusted operating earnings of $140M to $170M.

0 · Reply

Doozio Feb. 24 at 8:57 PM

$SUPN thing about eps gap goes during 🐒🍌🧠⏰♾️?

0 · Reply

kshonstocks Feb. 24 at 7:38 PM

fine volume bar on $SUPN

0 · Reply

ortega1963 Feb. 20 at 6:31 AM

$SUPN ascending Triangle

0 · Reply

NetworkNewsWire Feb. 17 at 2:05 PM

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A $OTLC $ARWR $MGTX $SUPN $JNJ https://ibn.fm/8zb4f

1 · Reply

Market Cap	2.79B
Revenue (ttm)	718.95M
Net Income (ttm)	-38.55M
EPS (ttm)	N/A
PE Ratio	19.43
Forward PE	27.97
Profit Margin	-5.36%
Debt to Equity Ratio	0.00

Volume	969,000
Avg Vol	761,966
Day's Range	N/A - N/A
Shares Out	58.04M
Stochastic %K	99%
Beta	0.54
Analysts	Strong Sell
Price Target	$62.83